Highlights on SSc-ILD from the ATS International Congress 2021 – Slide kit

Nuove analisi su SSc-ILD presentate al Congresso Internazionale ATS, 14-19 Maggio 2021

Nel seguente slide kit sono riportate le evidenze scientifiche più rilevanti su SSc-ILD emerse dal Congresso Internazionale ATS 2021:

• Associations between extent of fibrotic ILD and FVC at baseline and change in FVC in subjects with SSc-ILD in the SENSCIS trial (Denton CP et al)

• Effect of nintedanib on decline in FVC in patients with SSc-ILD by GAP stage and ILD-GAP index (Kreuter M et al)

• Decline in FVC in patients with SSc-ILD with and without cough (Kreuter M et al)

• Impact of FVC decline on hospitalization events in SSc-ILD: a joint model analysis using data from the SENSCIS trial (Kreuter M et al)

• Modelling short-term FVC changes from SENSCIS to long-term FVC course in SSc-ILD demonstrates clinically meaningful reduction of FVC decline and survival benefits (Hoffmann-Vold AM et al)

• Correlations between changes in FVC and imaging parameters in patients with SSc-ILD (Humphries et al)

• Continued treatment with nintedanib in patients with SSc-ILD (Highland et al)